BioCentury
ARTICLE | Company News

Pulmagen, Teijin deal

October 1, 2012 7:00 AM UTC

Pulmagen granted Teijin exclusive rights to develop and commercialize ADC3680 in Japan. Teijin plans to start Phase I testing of ADC3680 in Japan in April 2013 for asthma. The oral small molecule pro...